10:00AM VTX-PID Mediated Optimal Depletion of Anti-AAV Neutralizing Antibodies in Human Subjects Allows Expanded Patient Eligibility for Future AAV-Based Gene Therapies
Time: 10:00 am
day: Conference Day 2
Details:
• How to optimize patient benefit and optimal strategy for neutralizing antibody-positive subjects
• Sharing clinical data demonstrating success and challenges in AAV Nabs positive subjects with PK/PD modeling
• Exploring the potential of these therapies to expand patient eligibility and potentially improve patient outcomes
• Implementation in real life and providing access for all AAVs and patients considering benefit-risk
